Piper Sandler Reiterates Overweight Rating on Jazz Pharma

Summary

Piper Sandler has reaffirmed its Overweight rating and $147 price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) on September 15, highlighting it as one of the most undervalued NASDAQ stocks. This comes ahead of the expected data release from the HERIZON-GEA-01 clinical trial, focusing on progression-free survival.MSN

Impact Analysis

So basically, Piper Sandler is doubling down on Jazz Pharmaceuticals, calling it undervalued with a $147 price target, just as we’re on the cusp of some potentially game-changing clinical trial data from HERIZON-GEA-01. The timing here is key—reaffirming the rating right before the data drop suggests Piper Sandler sees a strong upside that the market might be underestimating. The interesting part isn’t just the reaffirmation; it’s the broader analyst consensus that paints Jazz as a ‘Strong Buy’ with an average target of $184.69, implying a significant upside from current levels Tip Ranks+ 2. Everyone’s focused on the upcoming trial data, but the real story might be how Jazz is positioned as a mid-cap with substantial growth potential, especially with recent FDA approvals Reuters. I’d read this as a signal to watch for a potential rally if the trial data meets expectations.